Faced with Falling Revenues, Tumbling Shares, Ciphergen Points to New ProteinChip System | GenomeWeb

Ciphergen’s rollercoaster revenue growth over the last few quarters — culminating in a hefty shortfall of expectations in the quarter that ended June 30 — has made investors wary, and its stock has tumbled to about half its value since the beginning of July. Meanwhile, the company has been pointing to a possible future upturn driven by new products and diagnostic tests, and has promised to rein in costs by making cuts in its instrumentation division.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.